Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $65
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice TargetHot
Oppenheimer analyst Suraj Kalia maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $85 to $65.
Oppenheimer analyst Suraj Kalia maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $85 to $65.